Roche CEO cites European pricing pressure; Baxter spinoff on track for midyear;

@FiercePharma: Dog data at AACR cancer confab may point to personalized treatments. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Chinese API maker Yunnan Hande Bio-Tech gets a second FDA warning letter. Report | Follow @EricPFierce

@CarlyHFierce: Pfizer's Lyrica team matches the spokesman to the message. FiercePharmaMarketing article | Follow @CarlyHFierce

> Roche ($RHHBY) CEO Severin Schwan said the company's oncology franchise will continue to drive growth, despite ongoing pricing pressure in Europe. Report

> Baxter International ($BAX) first-quarter earnings fell by 23%, partly because of negative currency effects; its biopharma spinoff remains on track for midyear, executives said. Report (sub. req.)

> Amgen ($AMGN) sales took an 11% leap in the first quarter, as its old standby Enbrel and newer Prolia/Xgeva franchise helped offset generic competition and currency effects. Release

> Two psychiatrists with financial ties to AstraZeneca ($AZN) quit a Texas state hospital after they were told they faced disciplinary action for taking speaking and consulting fees from the company. Report (sub. req.)

> The nursing home pharmacy services company Omnicare is working with financial advisers on a possible sale, Bloomberg says. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: WuXi and DNAnexus join up for cloud-based genomic services. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: FDA issues new guidelines on acceptance of data from overseas clinical trials. Story | Follow @VarunSaxena2

@EmilyWFierce: FBI admits to decades of flawed hair analysis. Washington Post story | Follow @EmilyWFierce

> Diabetes device sales bounce back at Abbott with FreeStyle Libre. More

> St. Jude aims for Axium approval before year-end, with robust neuromodulation growth in 2016. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Salk heavyweight Evans raising $33M for an intriguing stealth biotech. Article | Follow @FierceBiotech

@JohnCFierce: The next-next gen thing: Merck and Gilead square off in battle of the next-next-gen hep C combos. Report | Follow @JohnCFierce

> Take two: Is Clovis Oncology a buyout target? Item

> Juno and AstraZeneca pair two hot immunotherapies in new cancer study. Article

> Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview. Report

CRO News

> BioClinica recruits a new eClinical president amid rapid expansion. Item

> WuXi deepens its genomic ties with latest partnership. More

> India's Biocon eyes an IPO for its in-house CRO. Story

> Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars. More

> PPD reaches into China with a new central lab. Article

Vaccines News

> Mymetics-led consortium scores €8.4M to develop thermostable vaccines. More

> PaxVax expands commercial network for typhoid vaccine. Report

> CSL CFO to lead flu vaccine business after 2016 launch. Item

> Sinovac to trial jabs with potential to disrupt Pfizer, GSK in China. Story

> Potency worries prompt GSK flu vaccine recall. Article

Pharma Manufacturing News

> Study finds essential antibiotics are often in short supply in U.S. Item

> Indicted compounder filled prescriptions with fake patient names Silver Surfer, Coco Puff. Report

> Counterfeit Botox again found in the U.S. More

> Bayer to close vet med plant, lay off 130. Story

> Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. Article

Pharma Asia News

> Founder Dilip Shanghvi did not buy Daiichi stake, Sun Pharmaceutical says. Item

> China proposes patent law changes to toughen IP protection. More

> Biocon plans India listing for Syngene in R&D funding move. Report

> South Korea's SillaJen eyes Phase III for immunotherapy oncology candidate. Story

> Japan researchers look to upset apple cart of pharma manufacturing costs. Article

And Finally... The language we speak--and words we choose--appear to shape our thoughts and viewpoints. Report (sub. req.)